Innovating Works

PvRecur

Financiado
Using Plasmodium vivax genetic data to estimate the cause of recurrent vivax mal...
Malaria infects hundreds of millions of people year on year. The WHO is committed to a world ultimately free of malaria. Of the two most important causes of malaria, Plasmodium vivax is the most difficult to eliminate largely beca... Malaria infects hundreds of millions of people year on year. The WHO is committed to a world ultimately free of malaria. Of the two most important causes of malaria, Plasmodium vivax is the most difficult to eliminate largely because it has the capacity to relapse: causing recurrent malaria via the activation of latent liver-stage parasites. Recurrent malaria can also be caused by the failure to treat a previous blood-stage infection (recrudescence) and, in endemic settings, new infectious mosquito bites (reinfection). Knowing the cause of recurrent malaria is key to understanding malaria epidemiology and to providing efficacious treatment. For example, to evaluate the efficacy of a drug designed to kill P. vivax liver-stage parasites in an endemic setting, reinfections and recrudescence must be separated from relapses. However, there are no direct ways to diagnose the cause of recurrent malaria. To address this problem, I aim to build a tool (Pv3R) that uses Plasmodium vivax genetic data to estimate the probability of Relapse, Recrudescence and Reinfection, and use Pv3R to estimate the burden of relapse and its contribution to transmission, thereby validating Pv3R’s utility. I will achieve my objectives by merging my existing expertise in statistical malaria genetics with the expertise of Dr Michael White and his lab, its ties with field-based P. vivax epidemiology and its capacity to generate P. vivax genetic data. Working with Dr White, I will develop a state-of-the-art statistical inference method to tackle the challenging unsolved problem of differentiating between the causes of recurrent P. vivax. This will generate knowledge that directly improves our understanding of P. vivax epidemiology and, most long-lastingly, a public health resource (Pv3R) that can be used sustainably by the malaria community to generate more epidemiological knowledge and to guide the design of more effective treatment regimens needed for P. vivax control and elimination. ver más
06/11/2025
IP
212K€
Duración del proyecto: 31 meses Fecha Inicio: 2023-03-22
Fecha Fin: 2025-11-06

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-22
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
Presupuesto El presupuesto total del proyecto asciende a 212K€
Líder del proyecto
INSTITUT PASTEUR No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5